Bryleos secures $5M to develop a treatment for substance use disorder, and announces breakthrough BNAD101 study results
Summary
The study of 60 healthy adults demonstrated a 52% increase in intracellular NAD levels within just 5 days, effectively validating the potential of BNAD101 in treating conditions where swift response is critical - such as substance use disorder treatment and withdrawal. "Its rare to see a company incorporate principles of systems biology into an early stage trial, and Bryleos has gathered some impressive data using this approach. The proteomic and metabolomic results show BNAD101s impact on various biological networks, simultaneously meeting the studys primary endpoints while informing possibilities for future research," said Jim Health, Ph.D., President of the Institute for Systems Biology.NAD plays a vital role in regulating cellular energy levels and signaling pathways, which makes it crucial in promoting cellular regeneration. Bryleos novel oral composition of NAD+ offers the potential for treatment to be administered from anywhere, without the need for IV delivery, making it more affordable for the millions that so desperately need it.Early investor, television personality and former motorsport team owner Eddie Jordan emphasized, Bryleos lead asset, BNAD101, has the potential to revolutionize the healthcare industry and improve the lives of countless people, especially those struggling with addiction. Overall, this POC generated a substantial set of novel findings that support the Companys strategy and claims and provides further evidence for the critical role of NAD across several organ systems and biological pathways.